WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced a significant advancement in its cardiovascular portfolio with the issuance of a new patent for its drug istaroxime in Japan. The patent, entitled “Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF),” focuses on improved methods of administering the drug intravenously. This includes prolonged infusion times, which can be used independently or alongside other treatments, potentially offering enhanced outcomes in heart failure management compared to existing methods.
Istaroxime is a pioneering investigational therapy designed to enhance both systolic contraction and diastolic relaxation in the heart. It aims to aid in blood pressure elevation and support renal function while maintaining a favorable safety profile. This therapy has shown promise in four successful Phase 2 trials involving patients experiencing acute heart failure and the onset of cardiogenic shock due to heart failure.
Craig Fraser, Chairman and CEO of Windtree Therapeutics, emphasized the strategic importance of this development: “Continuing to expand and strengthen the Company’s cardiovascular platform patent estate is an important priority and we are pleased that this patent has been issued in the key country of Japan.”
The patent, registered as Patent No. 7560134, carries a registration date of September 24, 2024, and is set to expire in 2039. This milestone reflects Windtree’s ongoing efforts to advance treatment options for heart failure and reinforces its efforts in developing novel therapies, including next-generation oral SERCA2a activators. The company plans to keep stakeholders informed of its progress in expanding its intellectual property and therapeutic innovations.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.